Oncology

Oncology Grants

Grant and Contract AwardsAnnual Direct

Adams, D

Phase II Study of Rapamycin for Complicated Vascular Anomalies
R01 FD 00371209/22/09-07/31/13$258,707

Chhipa, R

Identifying survival factors for Diffuse Intrinsic Pontine Glioma (DIPG) Stem Cells
06/01/13-05/31/14$25,000

Chlon, T

Pelotonia Fellowship Program
03/01/13-02/28/15$39,264

Chow, L

Micro-RNA Expression in Pediatric High-Grade Glioma
-09/01/11-08/31/13$22,727
Molecular Targeting of High-Grade Astrocytoma
-10/01/11-09/30/15$130,435
Molecular Targeting of Pediatric High-Grade Glioma
07/01/11-06/30/14$110,000

Cripe, T

Neurofibromatosis Preclinical Consortium Center Award
2011-05-00307/01/11-06/30/13$204,545

DasGupta, B

Regulation of Forebrain Neurogenesis by the Energy Sensor AMP Kinase
R01 NS 072591-01A107/01/12-06/30/17$230,208

Dorris, K

Molecular Epidemiology in Children's Environmental Health Training Program
T32 ES 01095710/01/12-06/30/13$40,635

Drissi, R

Telomerase as a Marker and Therapeutic Target for Pediatric High-Grade Glioma
TCCCF01/01/13-12/31/13$60,000

Fouladi, M

Children's Oncology Group Chair
U10 CA 09854304/13/12-02/28/14$11,550
The Pediatric Brain Tumor Consortium
U01 CA 0815504/01/11-03/31/14$44,115
Establishment of an International Diffuse Intrinsic Pontine Glioma (DIPG) Registry
01/01/12-05/31/14$231,092
The Pediatric Brain Tumor Consortium - Per Patient
U01 CA 0815504/01/11-03/31/14$9,259

Geller, J

Epigenetic and Clinical Impact of SMARCB1 Loss in Cancer
R21 CA 16679007/01/2012-06/30/2014$9,273

Moreira Ridsdale, D

The Role of CDC42 in MLL-AF9 Induced AML Xenograft Model
06/01/13-05/31/14$5,000

O'Brien, M

Molecular Targeting of Chemotherapy-Resistant Pediatric Acute Myeloid Leukemia
O'Brien-HOW12/01/12-11/30/13$75,000

Perentesis, J

Children's Oncology Group Chair - Millennium
03/01/12-02/28/17$10,395
Children's Oncology Group Chair - Workload Intensity
U10 CA 09854303/01/12-02/28/17$27,791
Children's Oncology Group Phase I / Pilot Consortium
U01 CA 09745209/01/06-07/31/15$22,525
COG Supplemental Reimbursement
03/01/12-02/18/17$39,193
Pediatric Phase I - Pilot Consortium (per case)
UM1CA09745207/24/12-05/31/15$46,010
Pediatric Phase I Scientific Leadership
UM1CA09745209/26/12-07/31/15$11,501
Children's Oncology Group Phase I / Pilot Consortium - per patient
U01 CA09745209/01/06-07/31/12$125,705

Phillips, C

Genetic Model of Cytarabine Sensitivity in Children with AML
07/01/12-06/30/14$50,000

Privette, L

Cincinnati Interdisciplinary Women's Health Research Career Training Grant
K12 HD 05195307/01/12-06/30/14$79,933
Defining the Role of the DEK Oncogene in Breast Cancer Stem Cell Tumorigenicity Ad Pre-Clinical Testing of Therapeutic DEK Targeting Strategies
RCF04/01/13-03/31/14$40,000

Romick-Rosendale, L

Environmental Carcinogenesis and Mutagenesis
T32 ES 00725009/01/12-06/30/13$41,170

Weiss, B

Phase I Trial of the MEK 1 Inhibitor AZX6244 with Plexiform
02/01/12-01/31/14$37,182
Children's Oncology Group Chair - Workload Intensity
U10 CA 09854303/01/12-02/28/17$11,550

Wells, S

Fanconi Anemia and HPV Transformation
R01 CA 10235709/28/09-08/31/14$191,834
Role and Regulation of the Human DEK Proto-Oncogene
R01 CA 11631609/05/12-06/30/17$174,318
Targeting the Ron-DEK Signaling Axis in Breast Cancer
W81XWH-12-1-019409/01/12-08/31/14$125,000

Williams, J

ETV2 Role in Tumor-Induced Lymphangiogenesis, A Putative Therapeutic Target
07/01/12-06/30/14$69,659
Current Year Direct$2,610,576
Industry Contracts

Fouladi, M

$19,250

Geller, J

$73,615

Wagner, L

$2,887

Weiss, B

$12,890
Current Year Direct Receipts$108,642
Total$2,719,218